Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

Add ENTB Price Alert      Hide Sticky   Hide Intro
Moderator: ronrooster
Search This Board: 
Last Post: 6/22/2017 2:23:28 PM - Followers: 441 - Board type: Free - Posts Today: 0

                                     ENTB LATEST NEWS FROM JUNE 1, 2016:



?Zander Therapeutics is a biotechnology company focused on veterinary therapies that enlist the animals’ own immune system.  Zander’s main areas of interest include: autoimmune disorders such as arthritis, immunotherapies for cancer treatment in canines and bone marrow suppression therapy for animals treated with chemotherapy and radiation therapy.
??Learn more about bone marrow and aplastic anemia therapy as well as small molecule targeting cancer stem cell genes.


Products in Development for Veterinary Use

  • ZT 110 is an NR2F6 inhibitor feline leukemia
    ZT 240 is an NR2F6 inhibitor for canine cancer
    ?ZT 396 is an NR2F6 stimulator for exercise induced pulmonary hemorrhage (equine)
    ZT 430 is an NR2F6 stimulator for arthritis and autoimmunity (feline & canine)


Small Molecule Therapies Targeting Cancer Stem Cell Genes in Animals?

Small Molecule targeting of the cancer stem cell is the process of “coaxing” the cancer stem cell to turn into a normal cell. Regen BioPharma (licensor) has identified and filed patents on a novel gene controlling the process of cancer stem cell differentiation. Additionally, Zander Therapeutics has filed its own patent applications regarding therapies for animals.?
  • Objective is to identify small molecules that can induce differentiation of cancer stem cells 
    High through-put screening identified 7 “hit” compounds 
    Currently in pre-clinical development 
    Additional indications include solid tumors and acute leukemia


Small Molecule Therapies Targeting Autoimmune Diseases Genes in Animals

The Company believes that autoimmune diseases such as arthritis can be controlled and their impact reversed by activating a gene in animals that is believed to modulate this process.  This set of therapies is based upon intellectual property licensed by Zander Therapeutics from Regen BioPharma.  Zander Therapeutics is pursuing its own intellectual property that will build on currently licensed technology.
  • Objective is to identify small molecules that activate NR2F6 check point that appears to control autoimmune diseases

    Currently in pre-clinical development 


Bone Marrow and Aplastic Anemia Therapy

A personalized cellular therapeutic product designed to stimulate blood production in veterinary patients whose bone marrow is not properly functioning.
  • Fat stem cell-based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemotherapy or chronic conditions
    Uses animal’s own fat as a source of endothelial cells to heal damaged bone marrow 
    Toxicity studies have been successfully completed by Regen BioPharma Inc., the licensor of this technology to Zander Therapeutics
    Aims to provide “natural” replacement to synthetic cytokines
For cats and dogs, Zander will target:
  • Arthritis
    Autoimmune Disorders
    Feline Leukemia

For horses, Zander will target:
  • Exercise Induced Pulmonary Hemorrhage (EIPH)

United States Food and Drug Administration (FDA) Investigational New Drug Application (IND #15376, status cleared for use in humans by Regen BioPharma Inc. -- licensor to Zander Therapeutics Inc.)






Zander Therapeutics, Inc.
4700 Spring Street, Suite 304
La Mesa, CA 91942

Telephone: (619) 702-1404
Fax: (619) 330-2328



David R. Koos, PhD, DBA
Chairman and Chief Executive Officer

David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 32 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.

?Harry Lander, PhD, MBA
President and Chief Scientific Officer

Harry Lander has over 20 years of professional scientific, business and financial management experience related to biomedical research.  He has a deep knowledge of operations and research administration.  Dr. Lander has a team-oriented management style founded on outstanding communication and interpersonal skills.  Highly effective at strategic planning, problem solving and operational excellence.  Dr. Lander has extensive relationships with large and small biotechnology / pharmacology companies and entities that Regen BioPharma expects to leverage for company growth.

Formerly he has served as Research Chief / Administration for Sidra Medical and Research Center (Doha, Qatar), Assistant Provost for Weill Cornell Medical College (Cornell University), along with serving as Assistant Dean for Research Administration at Weill Cornell Medical College (Cornell University).

?Todd S. Caven
Chief Financial Officer 

Todd S. Caven is an accomplished executive with 30 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. In March of 2009, Mr. Caven co-founded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States.

In 2003, Mr. Caven founded Rock Ridge Enterprises, a Minnesota-based boutique Private Equity firm that focuses on the acquisition of manufacturing, distribution, construction and business services firms in the upper Midwest. Prior to founding Rock Ridge Enterprises, he served as the CFO of Atterro Human Capital Group (formerly Pro Staff), a $500 million privately held firm in the Staffing and Recruiting industry. Prior to Atterro, Todd held senior-level finance and marketing positions at Nordic Track and the Carlson Companies, both in Minneapolis, Minnesota. He started his career in corporate finance at Amoco Corporation in Chicago, Illinois (now British Petroleum).

Todd earned a Bachelors degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

Thomas Donnelly, DVM
Senior Veterinary Advisor

Tom is a board-certified specialist in the field of laboratory animal medicine. He is also Adjunct Associate Professor at Tufts University Cummings School of Veterinary Medicine and Professor (teaching & research) at Ecole Nationale Veterinaire d’Alfort. He provides regulatory guidance, research advice, medical attention and welfare supervision to researchers using animals in scientific investigation and testing. Tom is a board-certified specialist in the field of exotic mammals, and sees primary care and referred patients. His work links the understanding of animal diseases and their complexities with the development of novel therapies for humans and animals.

Linda L. Black, DVM, PhD 
Senior Veterinary Advisor

Linda is a leading researcher, published author and currently COO and Vice President of Clinical Science for Medicus Biosciences, a biotech company focused on drug delivery for ophthalmology, advanced wound healing, osteoarthritis, and regenerative medicine applications for pets and people. She has extensive experience in veterinary stem cell research and commercialization. She holds a PhD in Molecular and Cell Biology from The Wistar Institute at University of Pennsylvania School of Medicine, a DVM from University of Wisconsin School of Veterinary Medicine and attended undergraduate training at the University of California at Davis. She completed her post doctoral fellowship at GlaxoSmithKline.

?Thomas Ichim, PhD
Senior Research Consultant

Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. He spent over seven years as President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. 

?Debbie Dorsee
Director of Business Development

The Dorsee Company, founded by Debbie Dorsee, is a leader in public relations for businesses and individuals. With an integrated focus on community relations, marketing, fundraising/capital raising, and business development, The Dorsee Company offers a unique promotional approach that opens doors, forges partnerships, and drives results.
Debbie Dorsee, a San Diego native, founded The Dorsee Company in 2003. Drawing from her life’s fabric of political campaigns, social events and promotional fundraising, she uses her behind-the-scenes knowledge and community contacts to promote public awareness and drive business results. Debbie was the recipient of the San Diego North Chamber of Commerce’s Volunteer of the Year honor and was named one of San Diego Metropolitan Magazine’s Metro Movers to Watch



 Recent News!  Check out Zander therapeutics website.





Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTB News: Quarterly Report (10-q) 06/22/2017 02:11:24 PM
ENTB News: Current Report Filing (8-k) 05/31/2017 06:08:12 AM
ENTB News: Current Report Filing (8-k) 05/25/2017 06:06:14 AM
ENTB News: Quarterly Report (10-q) 04/03/2017 02:19:18 PM
ENTB News: Quarterly Report (10-q) 01/11/2017 10:29:57 AM
#38142   10 Q is out.Share structure still good. ronrooster 06/22/17 02:23:28 PM
#38141   Wonder if we get another Wednesday PR this ronrooster 06/19/17 11:22:28 AM
#38140   Unlimited potential .Perhaps ENTB should change its ticker symbol.gltu. ronrooster 06/18/17 01:10:17 PM
#38139   If ENTB does develop drug cures for inflammatory JokersWild12 06/18/17 01:03:57 PM
#38138   agree salesleader 06/17/17 02:57:37 PM
#38137   Over 4 years for myself.Entb/ZANDER is definitely the ronrooster 06/17/17 01:13:04 PM
#38136   I've held this for a couple years , salesleader 06/15/17 09:48:13 AM
#38135   Eyes will come.In mean time good to accumulate ronrooster 06/14/17 06:12:33 PM
#38134   salesleader 06/14/17 03:35:33 PM
#38133   I was lucky enough to get 22's a salesleader 06/14/17 03:35:33 PM
#38132   ENTB/ZANDER clearly demonstrating continual progress, especially towards canine ronrooster 06/14/17 10:43:24 AM
#38131   Excellent news! Kbro13 06/14/17 09:23:39 AM
#38130   Excellent news! Kbro13 06/14/17 09:23:38 AM
#38129   NEWS OUT.Entest BioMedical's Subsidiary Zander Therapeutics, Inc., Reports ronrooster 06/14/17 09:20:10 AM
#38128   More good news. Another piece added. The company JokersWild12 06/09/17 04:59:01 PM
#38127   Thanks.You are correct about the substance however when ronrooster 06/07/17 10:46:23 AM
#38126   Nice call on the News! Kbro13 06/07/17 10:37:57 AM
#38125   NEWS OUT. Entest BioMedical's Subsidiary Zander Therapeutics, Inc. ronrooster 06/07/17 09:24:40 AM
#38124   I AM sticking my neck out -News tomorrow ronrooster 06/06/17 03:23:16 PM
#38123   Any targets in mind? ronrooster 06/06/17 10:05:21 AM
#38122   no debt, ready to sell jeffshir 06/06/17 10:01:38 AM
#38121   Based on the speed of issuing and distributing ronrooster 06/05/17 03:12:14 PM
#38120   $34 trade to knock ENTB down 34%. ronrooster 06/02/17 03:54:18 PM
#38119   AGREE. Reminder to all longs to lock up ronrooster 06/02/17 12:48:57 PM
#38118   agree , patiently waiting here in Illinois ! salesleader 06/02/17 10:43:26 AM
#38117   Like the words forward progress referenced in this JokersWild12 06/02/17 12:41:02 AM
#38116   Entest BioMedical Inc. (PINK: ENTB) announced today that ronrooster 05/31/17 04:13:41 PM
#38115   I don't know. There is no conversion date SanDiegoAlan 05/31/17 03:57:16 PM
#38114   Understood but how long will that take...I understand convertible gotinearly 05/31/17 03:41:23 PM
#38113   They don't have to be tradable. They are SanDiegoAlan 05/31/17 12:45:30 PM
#38112   Faith or greed? SanDiegoAlan 05/31/17 12:31:49 PM
#38111   Currently, non-tradable gotinearly 05/31/17 12:31:46 PM
#38110   I agree and those are preferred shares at salesleader 05/31/17 11:52:05 AM
#38109   Not to mention they are accepting at a Harbintown 05/31/17 09:35:23 AM
#38108   8K out today. Looks like ENTB/ZANDER paying some ronrooster 05/31/17 09:32:30 AM
#38107   Correct, appears the only change is the convertible ronrooster 05/25/17 11:39:16 AM
#38106   The authorized shares haven't increased. Kbro13 05/25/17 11:31:55 AM
#38105   Agreed!!! WTF?????? WanMan 05/25/17 11:14:43 AM
#38104   Kooooooossss WTH are you doing??? don't drive this Crocs69 05/25/17 10:38:54 AM
#38103   FORM 8-K CURRENT REPORT Pursuant to Section 13 mrdrifter 05/25/17 09:39:14 AM
#38102   8K out today. ronrooster 05/25/17 09:33:52 AM
#38101   NEWS OUT>Entest BioMedical Inc. Subsidiary Zander Therapeutics Discusses ronrooster 05/23/17 02:05:36 PM
#38100   yea gotinearly 05/18/17 03:44:45 PM
#38098   3rd try finally got some of those low salesleader 05/17/17 12:09:40 PM
#38097   Absolutely correct.In the mean time try to accumulate ronrooster 05/16/17 12:23:15 PM
#38096   When ready, it will be tested on animals jeffshir 05/16/17 12:18:50 PM
#38095   Great.Too bad PR did not mention ENTB/ZANDER. ronrooster 05/16/17 11:47:27 AM
#38094   Regen BioPharma, Inc. Sees Additional Positive Results on gotinearly 05/16/17 08:32:19 AM
#38093   Brother BM$N is moving from the trips, hope 72chevnj 05/12/17 02:51:19 PM
#38092   ENTB/ZANDER due for some REAL news soon.imo Raise ronrooster 05/08/17 04:00:02 PM